Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial

Liang J.; Bi N.; Wu S.; Chen M.; Lv C.; Zhao L.; Shi A.; Jiang W.; Xu Y.; Zhou Z.; Wang W.; Chen D.; Hui Z.; Lv J.; Zhang H.; Feng Q.; Xiao Z.; Wang X.; Liu L.; Zhang T.; Du L.; Chen W.; Shyr Y.; Yin W.; Li J.; He J.; Wang L.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial

【24h】

Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial

机译：依托泊苷和顺铂与紫杉醇和卡铂，并在不可切除的胸部放射治疗III III非小细胞肺癌：多中心随机阶段III试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The optimal chemotherapy regimen administered currently with radiation in patients with stage III non-small cell lung cancer (NSCLC) remains unclear. A multicenter phase III trial was conducted to compare the efficacy of concurrent thoracic radiation therapy with either etoposide/cisplatin (EP) or carboplatin/paclitaxel (PC) in patients with stage III NSCLC.

机译：背景技术：目前施用的最佳化疗方案与III期非小细胞肺癌（NSCLC）患者的辐射仍然尚不清楚。进行多中心期III试验，以比较同时胸部放射治疗与阶段III型NSCLC患者的依托钠/顺铂（EP）或Carboplatin /紫杉醇（PC）的疗效。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2017年第4期|共7页
作者
Liang J.; Bi N.; Wu S.; Chen M.; Lv C.; Zhao L.; Shi A.; Jiang W.; Xu Y.; Zhou Z.; Wang W.; Chen D.; Hui Z.; Lv J.; Zhang H.; Feng Q.; Xiao Z.; Wang X.; Liu L.; Zhang T.; Du L.; Chen W.; Shyr Y.; Yin W.; Li J.; He J.; Wang L.;
展开▼
作者单位

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Wenzhou Med Univ Affiliated Hosp 1 Dept Radiat Oncol Wenzhou Peoples R China;

Sun Yat Sen Univ Ctr Canc Dept Radiat Oncol Guangzhou Peoples R China;

Shanghai Chest Hosp Dept Radiat Oncol Shanghai Peoples R China;

Tianjin Canc Hosp Dept Radiat Oncol Tianjin Peoples R China;

Beijing Canc Hosp Dept Radiat Oncol Beijing Peoples R China;

Fudan Univ Zhongshan Hosp Dept Radiat Oncol Shanghai Peoples R China;

Zhejiang Canc Hosp Dept Radiat Oncol Hangzhou Zhejiang Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Vanderbilt Univ Ctr Quantitat Sci 221 Kirkland Hall Nashville TN 37235 USA;

Chinese Acad Med Sci Canc Hosp Thorac Surg Natl Canc Center Epidem Res Lab Beijing Peoples R;

Vanderbilt Univ Ctr Quantitat Sci 221 Kirkland Hall Nashville TN 37235 USA;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Natl Canc Ctr Dept Med Oncol Beijing Peoples R China;

Peking Union Med Coll Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
non-small cell lung cancer; locally advanced; chemoradiotherapy; cisplatin and etoposide; carboplatin and paclitaxel;

机译：非小细胞肺癌;局部高级;化学疗法;顺铂和依托泊苷;卡铂和紫杉醇;

相似文献

外文文献
中文文献
专利

1. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial [J] . Liang J., Bi N., Wu S., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第4期

机译：依托泊苷和顺铂与紫杉醇和卡铂，并在不可切除的胸部放射治疗III III非小细胞肺癌：多中心随机阶段III试验
2. 9104 Randomized phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (CTR) for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group (WJTOG) 0105 [J] . N.Katakami, M.Satouchi, N.Yamamoto, European Journal of Cancer Supplements . 2009,第2期

机译：9104丝裂霉素/长春地辛/顺铂（MVP）与每周伊立替康/卡铂（IC）或每周紫杉醇/卡铂（PC）联合胸腔放疗（CTR）的不可切除的III期非小细胞患者的3期随机研究肺癌（NSCLC）：西日本胸腔肿瘤小组（WJTOG）0105
3. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer [J] . WangL., WuS., OuG., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第1期

机译：Ⅲ期非小细胞肺癌患者同时进行顺铂/依托泊苷或紫杉醇/卡铂联合胸腔放疗的II期随机研究
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001 [O] . Kana Watanabe, Yukihiro Toi, Atsushi Nakamura, 2021

机译：尿嘧啶/ TEGAFUR和顺铂的随机期II试验与培养基和顺铂具有同时胸部放射治疗用于局部先进的不可切除阶段III非鳞状非小细胞肺癌：NJLCG1001
7. C3-03: Randomized, phase III Study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small-cell lung cancer (NSCLC): WJTOG0105 [O] . Yoshida Kimihide, Uejima Hisao, Satouchi Miyako, 2007

机译：C3-03：丝裂霉素/长春地辛/顺铂（MVP）与每周依立替康/卡铂（IC）或每周紫杉醇/卡铂（PC）联合胸腔放疗（TRT）进行不可切除的III期非小细胞III期随机研究肺癌（NSCLC）：WJTOG0105

Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial

摘要

著录项

相似文献

相关主题

期刊订阅